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ABSTRACT  
 
Objective. Recommended outcome measures in osteoarthritis are standardized scales 
identical for each patient. As patient-specific scales are of increasing interest to consider 
patient’s priorities in outcome assessment, this study aims to validate individualized forms of 
the Western Ontario and McMaster Universities osteoarthritis index (WOMAC) function 
subscale. 
 
Patients and Methods. WOMAC function subscale data were prospectively obtained from 
1218 outpatients with hip or knee osteoarthritis requiring nonsteroidal anti-inflammatory 
drugs. Patients also rated the importance to get rid of disability in each activity of the 
WOMAC function subscale and select the 5 activities they considered the most important to 
be improved upon. After treatment, patients again completed the WOMAC function subscale. 
Several individualization methods were evaluated: methods whereby the score of each item is 
multiplied by, or added to, its importance and methods based on the 5 most important 
activities (WOMAC top 5). Psychometric properties of individualized scales were compared 
to those of the WOMAC function subscale. 
 
Results. Missing data rate was 11%, 13% and 2% for the WOMAC function, its 
individualized forms and the WOMAC top 5, respectively. Combining severity and 
importance of each item did not improve scales’ properties. The WOMAC top 5 was the most 
responsive scale (standardized response mean: 0.96 vs 0.80, p<0.0001). 
 
Conclusion. Because of its better responsiveness, ease of use, low missing data rate and 
ability to highlight patients’ priorities, the WOMAC top 5 could be an interesting tool in 
therapeutic evaluation in hip or knee osteoarthritis.  
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INTRODUCTION 
 
Patient-reported outcomes are increasing in interest in clinical practice and clinical research. 
In the setting of osteoarthritis (OA), a core set of outcome measures to be considered for 
phase III trials has been defined by the OMERACT (Outcome Measure in Rheumatology 
Clinical Trial); 3 domains should systematically be included: pain, physical function and 
patient global assessment.[1] The function subscale of the Western Ontario and McMaster 
Universities osteoarthritis index (WOMAC) is a valid, reliable, and responsive measure of 
functional impairment in hip and knee OA.[2-4] It is the most widely used condition-specific 
index, and the subscale is recommended to be included in all hip and knee OA trials.[1] 
However, the WOMAC function subscale is a standardized instrument that involves a fixed 
number of identical items, all having the same weight on the final score. Although the mean 
score is a measure of global functional impairment at the group level, the measure does not 
consider the variability in the importance to patients to be able to perform a particular activity. 
For example, the ability to climb stairs should be of poor importance in a patient who always 
takes a lift, or getting out of the bath should be of no importance for a patient who always 
takes showers. 
Questionnaires that principally focus on each patient’s priorities, so-called patient-specific or 
individualized instruments, have been developed and/or used in rheumatology.[5-12] These 
scales identify relevant issues at the individual level and allow the evaluation to focus on what 
is important to each patient. Some have shown better sensitivity to change than classical 
instruments.[6, 7, 13] But a few patient-specific scales have been applied in hip or knee 
disorders [7, 14] and none in lower limb OA requiring a medical intervention. As patients’ 
perspectives are matters of increasing importance,[15, 16] this prospective study aimed to 
develop and validate individualized scales derived from the WOMAC function subscale by 
several methods of individualization assessing functional impairment in patients with hip or 
knee OA and to compare their psychometric properties to those of the WOMAC function 
subscale. 
 
 
PATIENTS AND METHODS  
Study population 
Data were obtained from a prospective cohort study of 4 weeks’ duration involving 1362 
outpatients with hip (n=343) or knee (n=1019) OA as defined by the American College of 
Rheumatology.[17, 18] Between April 12 and July 31 2002, patients were recruited by 399 
French rheumatologists in private practice. Each rheumatologist was required to include 3 
patients with knee OA and 1 with hip OA. To be included in the study, patients had to 
experience pain from the OA (≥30 mm on a visual analogue scale (VAS) [0-100 mm]). Each 
patient gave an informed consent. All patients initially visited the rheumatologist in charge of 
their case and inclusion could begin with the onset of a nonsteroidal anti-inflammatory drug 
(NSAID) or with a switch from one NSAID to another. A final visit to the same 
rheumatologist was scheduled 4 weeks later.  
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Measurement 
At baseline visit, patients completed 3 self-administered questionnaires (figure 1): 
- The French-Canadian version of the WOMAC function subscale (5-point Likert 
version),[2] also termed as “severity questionnaire” in this paper, which is a 17-item 
scale addressing the degree of difficulty in accomplishing 17 activities of daily life. 
- The “importance questionnaire”:  patients had to rate how important it was to them to 
get rid of disability in each activity addressed by the WOMAC function items (from 
not important at all, to extremely important). Patients were randomly assigned to 3 
groups according to different response modalities for rating that questionnaire: 5-point 
(1-5) Likert scale (Likert 5 group), 3-point (1-3) Likert scale (Likert 3 group), or VAS 
[0-100 mm] (VAS group).  
- The “preference questionnaire”: patients had to select the 5 items of the WOMAC 
function they considered the most important by answering to the following question: 
“Could you choose from the 17-item list, the 5 you consider the most important to be 
improved upon?” 
Along these measures patients also assessed their pain and global disease activity on a 
VAS [0-100 mm]. And practitioners assessed each patient’s global disease activity on a 
VAS [0-100 mm]. 
At final visit, patients again completed the WOMAC function subscale.[2] 
To assess the test–retest reliability, a subsample of 93 patients, all from the Likert 5 group, 
were asked to complete, and send by mail, the WOMAC function subscale, the “importance” 
and the “preference” questionnaires again within 48 hours, before initiating NSAID therapy.  
Methods of individualization 
Several methods for individualization were used: 
(1) Individualized scales based on the importance questionnaire rated with a 5- or 3-point 
Likert scale or VAS.  
(a) With multiplicative methods: for each item the severity score was multiplied by the 
importance score, 
(b) With additive methods: for each item the severity score was added to the 
importance score.  
These scales were derived from both the WOMAC function subscale (17 items) and 
the WOMAC short-form subscale (8 items).[19]  
(2) The WOMAC top 5, based on the preference questionnaire, including the 5 most 
important items to each patient. Thus, the items of the WOMAC top 5 are not the same for all 
patients. 
Statistical analysis 
Because the psychometric performances of each scale were compared to those of the 
WOMAC function subscale, only patients who had completed this scale with no missing data 
at the baseline visit (n=1218) were involved in the development of the individualized forms 
(figure 1). Each scale was linearly transformed to a 0 to 100 scale, with a score of 0 indicating 
no disability and 100 indicating maximum possible disability. For each item, Spearman’s rho 
correlation coefficients between severity score and importance score were obtained. 
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Psychometric properties of each scale were evaluated, and properties of individualized scales 
were compared to those of the WOMAC function subscale. 
- Construct validity was assessed by Spearman’ rho correlation coefficient between the 
scores of each scale and that of the WOMAC function subscale. We examined 
divergent validity by the use of Spearman’s correlation coefficients between scores of 
individualized scales and other measures applied in this study (pain, patient and 
practitioner global assessment of disease activity).  
- Internal consistency was assessed when estimable (for fixed-item scales), with 
Cronbach’s alpha coefficient.[20] Estimation of confidence intervals and comparisons 
of Cronbach’s alpha coefficients involved use of bootstrapping methods, with 1000 
replications.[21]  
- Test–retest reliability was assessed with the intraclass correlation coefficient (ICC). 
ICC values vary from 0 (totally unreliable) to 1 (perfectly reproducible); an ICC≥0.75 
is regarded as excellent.[22] ICC confidence intervals were estimated with 
bootstrapping methods, with 1000 replications.[21] ICCs were compared with the 
likelihood ratio test.[23]  
- Responsiveness was assessed by the standardized response mean (SRM). SRM is the 
mean change in score between the baseline and the final visit divided by the standard 
deviation of the change in score.[24] SRM values can be considered large (>0.8), 
moderate (0.5-0.8) or small (<0.5).[25, 26] SRM confidence interval estimations and 
SRM comparisons involved use of bootstrapping methods, with 1000 replications.[21] 
Because final scores were calculated using the baseline importance questionnaire, 
SRM of scales using additive methods are arithmetically the same as the scale from 
which they are derived, so comparisons were not performed. 
Statistical analyses involved use of the SAS release 9.1 and R release 2.2.1 statistical software 
packages. 
 
 
RESULTS 
 
At baseline, the missing data rates were 11% (n=144), 13% (n=174) and 2% (n=21) 
for the WOMAC function subscale, its individualized derived forms and the WOMAC top 5, 
respectively. Baseline characteristics of the 1218 patients involved in analyses are reported in 
table 1 and were similar to those of patients with incomplete WOMAC function subscale data 
(n=144). Among these 144 patients, one patient did not complete the questionnaire, 71 
(49.3%), 53 (36.8%), 11 (7.6%) and 8 (5.7%) patients did not respond to 1, 2, 3 ore more than 
3 items. Baseline characteristics of patients in the Likert 5, Likert 3 and VAS groups did not 
differ.  
Mean scores for each scale and mean changes in score over the 4-week period are reported in 
table 2. Neither the WOMAC function subscale nor the individualized scales had a substantial 
ceiling or floor effect. For each item, the severity and importance scores were significantly 
correlated for each group (rho ranging from 0.34 to 0.67) However, for each activity of the 
WOMAC function subscale, some patients with a low severity score rated the item as very 
important, whereas a few patients with a high severity score for a given activity rated the item 
as being of little importance, except for item 13 (“getting in/out of the bath”) and item 16 
(“performing heavy domestic duties”) where some patients with high severity score rated the 
item as being of little importance (figure 2). 
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Construct validity  
All individualized scales were highly convergent with the WOMAC function subscale 
(rho≥0.75). Individualized scales involving all 17 items correlated more strongly with the 
WOMAC function subscale than shorter scales such as WOMAC top 5 or scales derived from 
the WOMAC short form. However, the additive scale using VAS for rating of importance was 
less correlated with the WOMAC function subscale than all other scales. Lower correlations 
(rho<0.5) were obtained between all scales, measuring functional status, and pain and global 
assessment of activity (table 3). 
Internal consistency   
Cronbach’s alpha coefficients of individualized scales involving all 17 items did not 
significantly differ from that of the WOMAC function subscale and ranged from 0.91 to 0.94 
(table 3). For scales involving 8 items (derived from the WOMAC short form), Cronbach’s 
alpha coefficients were significantly lower, ranging from 0.82 to 0.86. For the WOMAC top 
5, as the items involved in the scale were different for each patient, Cronbach’s alpha 
coefficient was not estimable. 
Test–retest reliability 
Among the 93 patients for whom test-retest reliability was assessed, necessary data to 
compute the WOMAC function subscale, its individualized forms and the WOMAC top 5 
were obtained for 71 (76%), 64 (69%) and 78 (83%) patients, respectively. The mean change 
in score between test and retest were of 4.76±11.46, 4.24±9.12, 4.24±9.23 and 6.42±16.48 for 
the WOMAC function subscale, its individualized form with multiplicative method and 
additive methods and the WOMAC top 5, respectively. The ICCs of individualized scales 
(long and short forms) did not significantly differ from that of the WOMAC function subscale 
(table 3) and were >0.75, except for the WOMAC top 5 (ICC=0.58).  
Responsiveness 
The SRM of the WOMAC function in the overall population was 0.80 (table 3). The 
SRM of the WOMAC function subscale was 0.78, 0.86 and 0.77 for the Likert 5, Likert 3 and 
VAS groups, respectively. The SRM of the 17-item individualized forms with multiplicative 
methods did not significantly differ from that of the WOMAC function subscale, except for 
scale using VAS for rating importance (0.85 vs 0.77, p=0.01). The WOMAC short form 
showed better responsiveness than the WOMAC function subscale (0.84 vs 0.80, p=0.002). 
However, the best sensitivity to change was obtained with the WOMAC top 5 (0.96 vs 0.80, 
p<0.0001).  
Sensitivity analyses 
Where there were less than 3 item missing, WOMAC function scores were computed 
with imputation of missing data, with the average value of the subscale, as recommended in 
the WOMAC user’s guide.[27] Analyses performed in this population of 1353 patients gave 
similar results as those obtained with data from 1218 patients, leading to the same 
conclusions. 
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DISCUSSION 
 
This study aimed to validate individualized measures of function impairment in hip or 
knee OA developed from the patient’s perspective by highlighting each patient’s priorities 
about functional improvement. All scales were derived from the WOMAC function subscale. 
Adding the measure of “importance” to the measure of “severity” provided complementary 
information. However scales combining the severity and importance of each item did not have 
better properties than the WOMAC function subscale, except with VAS used for rating of 
importance. The WOMAC top 5 was the best scale in term of responsiveness and missing 
data rate.  
Psychometric properties of the WOMAC function subscale found in this study are in 
accordance with those previously described and validated.[3, 4, 28-31] This study enrolled a 
large sample of patients with a wide range of severity of disease, which might allow the 
conclusions to be applied to a wide spectrum of patients with hip or knee OA. 
 
Because no consensus exists concerning the best way to individualize functional status 
instruments, we have evaluated 2 of the main possible individualization methods. In the first 
method, pre-specified items, identical for each patient, are preserved in the final score; 
individualization involves combining for each item rating of “severity” and “importance”.[7] 
In the second method, individualization is based on a selection process, patients are asked to 
specify or choose a limited (or not) number of areas they considered the most in need of 
improvement.[6, 9, 32] Then, patients are followed in terms of only these selected items. 
Moreover, both methods could be combined, for example, by rating the importance of the 
selected items. 
In this study, the WOMAC top 5 had a low rate of missing data and a good 
responsiveness. In addition, this scale is probably the most patient-specific scale because the 
selection process ensures inclusion of only clinically relevant activities to each patient. 
Furthermore, a SRM of 0.96 is large in a study involving pharmacological therapy 
intervention (NSAIDs); greater values of responsiveness had been found mainly when the 
intervention was a surgical joint replacement and when response was integrated over multiple 
observed time points.[4, 33] The WOMAC top 5 displayed fair reliability. However, the ICC 
exceeded 0.5, which is the minimal necessary precondition for appropriate application of a 
change score and evaluation of responsiveness.[34] One hypothesis to explain the smaller 
ICC observed for the WOMAC top 5 could be due to the within-patient change during the 
first 48 hours. However this point is unlikely to explain entirely the phenomenon, as shown in 
the analysis of the variation in score in these patients during this period that was moderate 
(mean change of 6.42 for the top5 versus 4.24 to 4.76 for other scales) and in the graphical 
analysis of Bland and Altman plots that did not reveal major systematic change in score (data 
not shown). Guyatt et al. distinguished 2 kinds of measurement instruments: discriminative 
instruments, which measure the difference between subjects, and evaluative instruments, 
which measure change over time and treatment effects.[35, 36] In the setting of OA, outcome 
measures such as the WOMAC function subscale or its individualized forms, are primarily 
assumed to be efficient for evaluative purposes. The key issue in developing evaluative 
instruments is to improve their responsiveness, to allow reducing the sample sizes when 
designing clinical trials or developing tools for more precise treatment comparison. From this 
assumption, the most valuable scale is the WOMAC top 5.  
Shorter tools such as WOMAC top 5 and WOMAC short form could be of interest in 
terms of feasibility (ease of use, time for completion, lower missing data rate) but also 
relevance of content. Actually, some activities addressed in the WOMAC function subscale 
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(4/17) are not performed by 5% to 30% of patients in their daily life [37] and thus are not 
relevant to them. Among these 4 items, 3 have been excluded in the WOMAC short form.[19] 
These items generated more missing data than the others and, if numerous, generated higher 
missing data rate for the overall score. The WOMAC top 5 reduces these 2 drawbacks by 
including only relevant activities for each patient. These findings support the fact that in case 
report forms, shorter scales could result in better data quality. 
The importance of improving ability to perform an activity was closely related to level 
of disability in that particular activity (figure 2). For each activity, when rating severity, 
patients may also take into account the importance of being able to perform it, not just their 
ability to perform it. These findings could explain why most of scales developed with 
methods combining, for each item, severity and importance showed psychometric 
performances not significantly different from those of the scale from which they were derived 
(long or short form). However, data showed that overlap between the rating of severity and 
importance was incomplete (figure 2). Thus, in clinical practice, assessment of importance for 
improvement in each area of function may provide complementary information to assessment 
of functional status alone. Moreover, such patient-centred approach might reinforce the 
patient-physician relationship in clinical practice.[38] 
We evaluated the impact of the response modalities (Likert 5, Likert 3 and VAS) used 
for rating importance. In most studies comparing values of VAS or multiresponse-mode 
scales,[2, 33, 39-41] both scales had similar results. Some authors encourage the use of the 
Likert scale [41-43] because of its ease of use and interpretation. Others encourage the use of 
the VAS [26] because of its better precision and sensitivity to change.[44, 45] We found that 
scales involving VAS were more sensitive to change. However, the increase in responsiveness 
was small compared to the complexity addressed by this method in data management.  
 
The use of individualized versions of WOMAC function subscale, we herein 
developed, enables highlighting patients’ concerns not only in therapeutic evaluation but also 
in identification of patients’ priorities for improvement in clinical practice. Nevertheless, in 
our study, the use of a pre-established list of items did not offer patients the opportunity to 
provide supplemental items of relevance to them, which might be a limitation to our 
individualization methods, but is of more practical use particularly in case reported forms in 
the setting of clinical trials. These scales allow for determining whether each patient’s 
priorities, in terms of functional improvement, are attained, the priorities having been 
established before treatment initiation. However, patient’s priorities may change over time, 
due to response shift or, for instance, with improvement deterioration or change in physical 
environment. In this study, we did not investigate these changes. Another potentially 
important question is to determine the optimal number of item to increase responsiveness with 
preservation of measure precision. This has not been investigated in this study were patients 
had to select exactly 5 items, but this could be an interesting topic for future research. 
 
Individualization by combining severity and importance for each WOMAC function 
item did not improve scale psychometric performances but provided complementary 
information on patients’ priorities that could be relevant in clinical practice. Among all scales, 
because of its better sensitivity to change, ease of use, lower rate of missing data and better 
reflection of patients’ concerns, the WOMAC top 5 could be an interesting tool in therapeutic 
evaluation and decision making for patients with hip or knee OA. It could be easily included 
in OA trials and used in addition to the WOMAC function subscale by adding only the 
preference questionnaire. The WOMAC top 5 requires further validation in independent 
samples of subjects from the target population.  
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CAPTIONS OF FIGURES 
 
Figure 1: Flow-chart 
 
Figure 2: Patterns of “jittered” plots of severity against importance scores, for items 
“descending stairs”, “standing” and “getting in/out of the bath” for the VAS group.  
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